Prestige Consumer Healthcare Inc.
PBH
$55.13
+5.05%
Prestige Consumer Healthcare Inc. is a leading pure-play over-the-counter (OTC) healthcare company with a diverse portfolio of established brands in niche consumer health categories such as eye care, motion sickness relief, and feminine hygiene. The company operates as a category leader and trusted provider, with many of its brands like Clear Eyes and Monistat holding dominant market positions and professional recommendations. The current investor narrative is heavily influenced by its recent strategic acquisition of the Breathe Right brand, a move aimed at expanding its reach into the growing wellness category, which is juxtaposed against a backdrop of significant stock price volatility and underperformance relative to the broader market, raising questions about execution and integration risks.…
PBH
Prestige Consumer Healthcare Inc.
$55.13
Related headlines
Investment Opinion: Should I buy PBH Today?
Rating: Hold. The thesis is that PBH presents a high-risk, potentially high-reward opportunity for value investors willing to bet against extreme pessimism, but the severe negative momentum and execution overhang necessitate a cautious stance until evidence of a turnaround emerges.
Supporting evidence includes the compelling forward P/E of 10.9x, which is a 45% discount to the trailing P/E and implies significant earnings growth. Analyst EPS estimates average $5.64, suggesting a derived fair value of ~$61.50, or 17% upside. The company's fundamentals are solid with strong gross (55.8%) and operating (29.6%) margins, a robust current ratio of 4.20, and a manageable debt load. However, the negligible trailing EPS of $0.05 and catastrophic 1-year price decline of -39% counterbalance these positives.
The thesis would upgrade to a Buy on successful Breathe Right integration evidenced by margin stability and revenue accretion in upcoming quarters, or a sustained technical reversal above the 52-week low support. It would downgrade to a Sell if the stock breaks decisively below $51.28, if forward EPS estimates are meaningfully cut, or if operating margins show signs of compression. Relative to its own history and the implied growth from its forward multiple, the stock appears fairly valued to slightly undervalued, but this valuation is contingent on successful execution that the market currently doubts.
Sign up to view all
PBH 12-Month Price Forecast
The outlook for PBH is bifurcated and hinges entirely on execution of its new growth strategy. The valuation is undemanding if the company can deliver on forward earnings, but the catastrophic price action suggests the market has serious doubts. The base case of stabilization and slow grind higher is most probable, but the wide dispersion of outcomes (bull target ~$75, bear target ~$50) reflects the binary nature of the investment. The stance is neutral due to the high uncertainty; confidence is medium as the strong margin profile provides a floor, but the lack of earnings visibility caps the ceiling. The stance would upgrade to bullish on confirmation of acquisition success and bottom-line EPS expansion, or downgrade to bearish on a breakdown below $51.28 or a cut to forward earnings estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Prestige Consumer Healthcare Inc.'s 12-month outlook, with a consensus price target around $71.67 and implied upside of +30.0% versus the current price.
Average Target
$71.67
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$44 - $72
Analyst target range
Analyst coverage for PBH is extremely limited, with only one analyst providing estimates, which implies the stock is a small-to-mid-cap name with limited institutional research and can suffer from higher volatility and less efficient price discovery. The single analyst provides an estimated EPS range of $5.54 to $5.91, with an average of $5.64; applying the forward P/E of 10.9x to the average EPS implies a potential price target of approximately $61.50, which would represent a 17.2% upside from the current price of $52.48, though this is a derived estimate rather than a published consensus target. The wide implied target range based on EPS estimates and the lack of a formal published price target spread signal high uncertainty and low conviction among the analyst community, leaving investors to rely more heavily on their own assessment of the acquisition's success and the company's ability to stabilize its financial performance.
Bulls vs Bears: PBH Investment Factors
The investment debate for PBH is a classic clash between deep value and broken momentum. The bull case is anchored in a compelling valuation (10.9x forward P/E), strong underlying margins, and an oversold technical setup near 52-week lows. The bear case is driven by catastrophic price action, negligible reported EPS, and profound skepticism around the company's growth strategy and acquisition execution. Currently, the bearish evidence from momentum and sentiment is stronger, as the stock's severe underperformance is a clear market verdict. The single most important tension is whether the Breathe Right acquisition can successfully reignite growth and justify the forward earnings expectations embedded in the valuation, or if it will become a costly distraction that confirms the market's worst fears.
Bullish
- Deeply Oversold Technicals: The stock is trading at $52.48, just 5% above its 52-week low of $51.28, following a severe 1-year decline of -39.0%. This extreme oversold condition, coupled with a historically low beta of 0.469, suggests the recent sell-off may be overdone, presenting a potential value entry point.
- Strong Forward P/E Valuation: The stock trades at a forward P/E of 10.9x, a significant discount to its trailing P/E of 19.9x. This forward multiple implies the market expects a substantial earnings recovery, with analyst EPS estimates averaging $5.64, which translates to a derived price target of ~$61.50, offering 17.2% upside.
- Robust Profitability Margins: The company exhibits strong underlying profitability with a gross margin of 55.8%, an operating margin of 29.6%, and a net margin of 18.9%. These healthy margins, combined with a solid current ratio of 4.20 and manageable debt-to-equity of 0.57, provide a stable financial foundation for navigating current headwinds.
- Strategic, Accretive Acquisition: The recent acquisition of the Breathe Right brand is a strategic move to expand into the growing wellness category. The acquisition is described as financially accretive, potentially providing a new growth vector to complement the company's portfolio of established, category-leading OTC brands.
Bearish
- Severe Negative Momentum & Underperformance: The stock has experienced catastrophic underperformance, down 23.9% in one month and 39.0% over one year, vastly underperforming the S&P 500 (+22.2% 1Y). This extreme, accelerating negative momentum indicates deep-seated investor concerns about fundamentals or execution that are not yet resolved.
- Minimal Bottom-Line Earnings: Despite strong margins, the diluted EPS is only $0.05, indicating significant pressure on the bottom line from non-operating expenses or share count dilution. This disconnect between high margins and negligible EPS raises questions about true earnings power and capital allocation efficiency.
- Extremely Limited Analyst Coverage: Only one analyst provides estimates for PBH, signaling low institutional interest and high uncertainty. The wide implied EPS range ($5.54 to $5.91) and lack of formal price targets reflect low conviction and leave investors with poor visibility, contributing to heightened volatility and inefficient price discovery.
- Integration & Execution Risk: The recent stock collapse coincides with the announcement of the Breathe Right acquisition, suggesting the market is skeptical of the deal's benefits. The company faces significant execution and integration risks, and any misstep could further erode investor confidence in its growth strategy.
PBH Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -39.0% and a 6-month decline of -17.9%. As of the latest close of $52.48, it is trading near the bottom of its 52-week range ($51.28 to $89.37), positioning it at just 5% above its 52-week low, which suggests the stock is deeply oversold and may represent a value opportunity, though it also signals persistent negative momentum and fundamental concerns. Recent momentum is decisively negative and accelerating, with a 1-month plunge of -23.9% and a 3-month drop of -14.3%, both significantly underperforming the S&P 500's respective -4.28% and -4.0% moves, indicating severe stock-specific selling pressure and a divergence from any broader market recovery. Key technical support is firmly at the 52-week low of $51.28, with resistance far above near the 52-week high of $89.37; a breakdown below $51.28 would likely trigger further capitulation, while a sustained move above this level is needed for stabilization. The stock's low beta of 0.469 indicates it has been historically less volatile than the market, making its recent extreme underperformance an anomalous and concerning event for risk assessment.
Beta
0.47
0.47x market volatility
Max Drawdown
-41.1%
Largest decline past year
52-Week Range
$51-$89
Price range past year
Annual Return
-33.5%
Cumulative gain past year
| Period | PBH Return | S&P 500 |
|---|---|---|
| 1m | -17.9% | -2.0% |
| 3m | -12.2% | -4.8% |
| 6m | -12.9% | -2.1% |
| 1y | -33.5% | +30.4% |
| ytd | -9.9% | -3.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PBH Fundamental Analysis
Revenue trajectory analysis is limited due to missing quarterly data, but analyst estimates for the upcoming period average $1.37 billion, providing a forward-looking benchmark; the company's strategic acquisition of Breathe Right is intended to be accretive and drive future top-line growth, though the recent stock collapse suggests investor skepticism regarding this growth plan. Profitability metrics show a company with solid underlying margins but minimal earnings per share; the trailing net margin is a healthy 18.9%, gross margin is strong at 55.8%, and operating margin is 29.6%, yet the diluted EPS is only $0.05, indicating significant non-operating expenses or share count dilution that is pressuring bottom-line results. The balance sheet appears healthy with a robust current ratio of 4.20 and a moderate debt-to-equity ratio of 0.57, suggesting ample liquidity and a manageable debt load; however, the return on equity of 11.7% and return on assets of 6.1%, while positive, are not exceptionally high, indicating room for improved capital efficiency to drive shareholder returns.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PBH Overvalued?
Given the positive net margin, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 19.9x and a forward P/E of 10.9x; the significant discount of the forward multiple implies the market expects a substantial recovery in earnings, likely tied to the integration of the Breathe Right acquisition and cost management initiatives. Peer comparison data is unavailable in the provided dataset, preventing a direct sector premium/discount analysis; however, a trailing P/E near 20x for a company in the stable OTC healthcare sector with recent severe price declines suggests the market may be pricing in elevated risk or growth concerns not reflected in the multiple alone. Historical context for the stock's own valuation range is also unavailable due to missing historical ratios data, making it difficult to assess whether the current P/E represents a cyclical low or a new normal based on revised fundamental expectations.
PE
19.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks center on the company's ability to translate strong operational margins into meaningful shareholder earnings. The trailing net margin of 18.9% is healthy, but the diluted EPS of $0.05 reveals significant bottom-line leakage, potentially from acquisition-related costs or other one-time items. The balance sheet is sound with a current ratio of 4.20 and debt-to-equity of 0.57, but the returns (ROE of 11.7%, ROA of 6.1%) are modest, indicating capital efficiency is an area for improvement, especially as it integrates a new acquisition.
Market and competitive risks are pronounced given the stock's valuation compression. The forward P/E of 10.9x suggests the market has already priced in significant pessimism, but further multiple contraction is possible if the Breathe Right integration falters or if the stable OTC healthcare sector falls out of favor. The stock's low beta of 0.469 makes its recent 23.9% monthly plunge an extreme anomaly, highlighting severe stock-specific risk that overrides its historical defensive characteristics. Competitive pressure in the OTC space and potential for the acquisition to distract from core brand management are ongoing external threats.
The worst-case scenario involves a failure to execute on the Breathe Right acquisition, leading to write-downs and sustained earnings disappointment. This could trigger a complete loss of investor confidence, pushing the stock through its key technical support at the 52-week low of $51.28. A realistic downside could see the stock re-testing its 52-week low, representing a -2.3% decline from current levels, or falling further towards levels implied by a distressed multiple on lowered earnings, potentially resulting in a total drawdown approaching the stock's recent max drawdown of -41.1% from its highs.
FAQ
The key risks are, in order of severity: 1) Execution/Integration Risk: Failure of the Breathe Right acquisition to drive growth could permanently impair the investment thesis. 2) Earnings Risk: The gap between strong margins (29.6% operating) and negligible EPS ($0.05) may persist, disappointing investors expecting the forward P/E to be justified. 3) Sentiment & Liquidity Risk: With only one analyst covering the stock (low coverage) and a high short ratio of 5.99, the stock is prone to exaggerated moves on news and suffers from poor price discovery. 4) Technical Risk: Trading just 5% above its 52-week low, a break below $51.28 could trigger accelerated technical selling.
The 12-month forecast is wide-ranging due to high uncertainty. The base case (50% probability) sees the stock stabilizing between $58 and $62, driven by slow progress towards analyst EPS estimates of ~$5.64. The bull case (25% probability) targets $70-$75 on successful acquisition integration and a valuation re-rating. The bear case (25% probability) warns of a drop to $48-$52 if execution falters and support at $51.28 breaks. The most likely scenario is the base case, predicated on the assumption that the company's strong margin profile prevents a total collapse, but that investor skepticism limits a rapid recovery.
Based on forward earnings, PBH appears undervalued. Its forward P/E of 10.9x is a steep discount to its trailing P/E of 19.9x, implying the market expects a sharp earnings recovery to an average analyst estimate of $5.64 per share. However, this 'undervaluation' is contingent on that earnings materializing. Given the stock's crash and the market's clear skepticism, the current price suggests the company is fairly valued or even overvalued if the growth plan fails. The valuation thus implies the market is paying a fair price for significant uncertainty, not a discount for a sure thing.
PBH is a high-risk, potentially high-reward stock that may be a good buy only for specific investors. For contrarian value seekers, the forward P/E of 10.9x and 17% implied upside to derived targets are attractive, and the stock is deeply oversold. However, the severe negative momentum (-39% 1Y), negligible trailing EPS, and high execution risk around its major acquisition make it a speculative bet. It is not a good buy for risk-averse or income-seeking investors, but could fit a small, high-conviction position in a diversified portfolio betting on a turnaround.
PBH is unsuitable for short-term trading due to its low beta (0.469), which typically implies low volatility, but its recent extreme moves are driven by stock-specific news, making it unpredictable. It is also not a traditional long-term 'buy-and-hold' growth stock given its recent struggles. It is best approached as a medium-to-long-term (2-3 year) special situation or turnaround investment. This horizon allows time for the Breathe Right integration to prove itself and for the company to demonstrate it can convert its strong margins into meaningful, growing EPS. Investors should be prepared for significant volatility along the way.